US Global Pricing Pressure: MFN Tariffs, Section 301, and Onshoring

The branded drug tariff deadline arrives Friday (July 17, 2026) under Section 232, with a three-tier compliance framework (0%/20%/100%) affecting 17 companies; a detailed importer guide is now available. The July 31 deadline for branded pharma tariffs/MFN is imminent, with $500B in investment at stake. Industry lacks tariff experience, and investor caution is high. A new event study on voluntary MFN deals (TrumpRx) shows investors did not panic—Pfizer's first agreement triggered positive reactions. A one-year review confirms all 17 TrumpRx deals are signed and the TrumpRx.gov site is live. The US Section 301 probe has expanded to France, Spain, Italy, and now Germany—the largest EU5 market—with a September 22 hearing. The UK deal (non-binding MoU) serves as a template, with Greer threatening '301 waiting in the wings' for Australia. Japan is amending its honebuto draft to elevate MFN and link inflation to FY2027 off-year revision; MHLW reconvened the HSC regulation panel. PhRMA publicly endorsed Japan's honebuto direction but urged action this year. Eli Lilly CEO warns Japan's pricing cuts drive away R&D. New analysis positions Japan's honebuto as a blueprint for Europe's pharma competitiveness. AstraZeneca Japan chief directly links MFN response to domestic pricing reform. A deep dive into Japan's FY26 NHI drug price revision reveals a new G1 repricing framework and inclusion of biologics, with deferred price cuts. South Korea has implemented flexible pricing contracts, fast-track reimbursement, and a generic pricing overhaul to 45% of originals to mitigate MFN exposure. MFN is already reshaping R&D and launch sequencing: 25% drop in small molecule trials post-IRA, 35% decline in European launches post-MFN EO, and new analysis suggests MFN may cause companies to delay or skip non-US launches. AstraZeneca has publicly confirmed that MFN is reshaping its US launch pricing strategy, with the US now referencing a basket of countries. New analysis indicates MFN demands are slowing price negotiations in Europe. An upcoming ISPOR workshop (2026) will feature industry, academic, and HTA perspectives on MFN's impact on European pricing and access. Germany enacted the GKV-BStabG reform: fixed 15.5% total manufacturer markdown (8.5% additional), tightened AMNOG price-volume discounts, and a new 9% vaccine markdown. The Pharma Dialogue resolution hints at future exemptions for domestic production. AIPM Hungary warns of a 43% drop in launches and a 'legally toxic market' due to reference pricing. APIs are exempt from new forced-labor tariffs, but medical devices are not. The 2026 EU-India FTA eliminates TRIPS-plus patent provisions. France will enforce biosimilar substitution from Sept 1, 2026. Tariffs are accelerating a structural shift of pharma investment to the US, while Europe risks industrial erosion. New analysis from two studies provides causal evidence that reference pricing causes launch delays in lower-income EU countries and that the Medicaid best-price clause actually raises commercial prices. A comprehensive overview of US MFN models (GENEROUS, GLOBE, GUARD, BALANCE) clarifies the policy architecture and interactions with IRA. Nuanced analysis shows how coverage restrictions and payer accommodation can shift MFN price benchmarks. India's NPPA has issued 103 notices for drug overpricing. AARP study estimates $197B in savings over 5 years from MFN on top 10 Medicare drugs. The Sheehy Bill (USTRx Act) proposes a chief pharma trade negotiator and annual reviews of foreign pricing policies.